dc.contributor.author | Uzun, O | |
dc.contributor.author | Kocagoz, S | |
dc.contributor.author | Cetinkaya, Y | |
dc.contributor.author | Arikan, S | |
dc.contributor.author | Unal, S | |
dc.date.accessioned | 2019-12-16T09:19:09Z | |
dc.date.available | 2019-12-16T09:19:09Z | |
dc.date.issued | 1997 | |
dc.identifier.issn | 0066-4804 | |
dc.identifier.uri | https://doi.org/10.1128/AAC.41.5.1156 | |
dc.identifier.uri | http://hdl.handle.net/11655/19628 | |
dc.description.abstract | The in vitro activity of LY303366, a new echinocandin derivative, was evaluated with 191 yeast isolates by a broth microdilution method. The MICs at which 50% of the isolates were inhibited were 0.125 mu g/ml for Candida albicans and C. tropicalis, 0.25 mu g/ml for C. krusei, C. kefyr, and C. glabrata, and 2.0 mu g/ml for C. parapsilosis. | |
dc.language.iso | en | |
dc.publisher | Amer Soc Microbiology | |
dc.relation.isversionof | 10.1128/AAC.41.5.1156 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Microbiology | |
dc.subject | Pharmacology & Pharmacy | |
dc.title | In Vitro Activity Of A New Echinocandin, Ly303366, Compared With Those Of Amphotericin B And Fluconazole Against Clinical Yeast Isolates | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Antimicrobial Agents And Chemotherapy | |
dc.contributor.department | Kimya | |
dc.identifier.volume | 41 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 1156 | |
dc.identifier.endpage | 1157 | |
dc.description.index | WoS | |